Pattern of use and efficacy of daratumumab-based therapy in patients with relapsed/refractory light chain amyloidosis in a real-world setting: a single institution experience

Leuk Lymphoma. 2022 May;63(5):1246-1250. doi: 10.1080/10428194.2021.2018585. Epub 2022 Jan 2.

Authors

Danai Dima¹, Xiao Hu², Joshua Dower², Diana Zhang³, Raymond Comenzo⁴, Cindy Varga⁴

Affiliations

¹ Hematology/Oncology Division, Cleveland Clinic Foundation, Cleveland, OH, USA.
² Hematology/Oncology Division, Tufts Medical Center, Boston, MA, USA.
³ Internal Medicine Division, Massachusetts General Hospital, Boston, MA, USA.
⁴ The John C Davis Myeloma and Amyloid Program in the Division of Hematology-Oncology, Tufts Medical Center, Boston, MA, USA.

PMID: 34978254
DOI: 10.1080/10428194.2021.2018585

No abstract available

Publication types

Letter

MeSH terms

Amyloidosis* / diagnosis
Amyloidosis* / drug therapy
Antibodies, Monoclonal / therapeutic use
Humans
Immunoglobulin Light-chain Amyloidosis* / diagnosis
Immunoglobulin Light-chain Amyloidosis* / drug therapy
Multiple Myeloma*
Treatment Outcome

Substances

Antibodies, Monoclonal
daratumumab